Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Cytokinetics, Inc.    CYTK   US23282W1009


News SummaryMost relevantAll newsSector news 

CYTOKINETICS : Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet

08/19/2011 | 08:40am US/Eastern
Results from These Trials Form the Basis For Ongoing Phase IIb Activities in Collaboration with Amgen

South San Francisco, CA - August 19, 2011

omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet. These two manuscripts present data regarding the safety, tolerability, pharmacokinetics and pharmacodynamic effects of this investigational drug candidate from a Phase I first-time-in-humans clinical trial in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients, each sponsored by Cytokinetics. Together, these publications provide evidence for the translation into humans of this unique mechanistic approach to activating cardiac muscle contractility and support the further development of omecamtiv mecarbil as a potential treatment for heart failure. Amgen Inc. holds an exclusive, worldwide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.

React to this article
Latest news on CYTOKINETICS, INC.
01/29 CYTOKINETICS : to Announce Fourth Quarter Results on February 12, 2015
01/02 C : tokinetics to Host 1/5/15 Conference Call to Discuss Expansion of Collaborat..
2014 CYTOKINETICS : And astellas announce expansion of collaboration for development ..
2014 CYTOKINETICS : Entry into a Material Definitive Agreement, Unregistered Sale of ..
2014 ASTELLAS PHARMA : Cytokinetics and Astellas Announce Expansion of Collaboration ..
2014 CYTOKINETICS : Other Events (form 8-K)
2014 CYTOKINETICS : Announces Presentations Relating to Tirasemtiv & Effects on Respi..
2014 CYTOKINETICS : Announces Presentations Relating to Tirasemtiv and Effects on Res..
2014 CYTOKINETICS : Announces Presentations Relating to Tirasemtiv at the 25th Intern..
2014 CYTOKINETICS : Assigned Patent
Income Statement Evolution
More Financials
Dynamic quotes